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To develop new vaccine candidates for flavivirus infections, we have engineered two flaviviruses, yellow fever virus (YFV) and West Nile
virus (WNV), that are deficient in replication. These defective pseudoinfectious viruses (PIVs) lack a functional copy of the capsid (C) gene in
their genomes and are incapable of causing spreading infection upon infection of cells both in vivo and in vitro. However, they produce
extracellular E protein in form of secreted subviral particles (SVPs) that are known to be an effective immunogen. PIVs can be efficiently
propagated in trans-complementing cell lines making high levels of C or all three viral structural proteins. PIVs derived from YFV and WNV,
demonstrated very high safety and immunization produced high levels of neutralizing antibodies and protective immune response. Such
defective flaviviruses can be produced in large scale under low biocontainment conditions and should be useful for diagnostic or vaccine
applications.
© 2006 Elsevier Inc. All rights reserved.Keywords: Pseudoinfectious viruses; Flavivirus vaccines; Subviral particlesIntroduction
The Flavivirus genus of the family Flaviviridae contains a
variety of important human and animal pathogens. Almost 40
members of this genus are capable of causing human disease. In
nature, flaviviruses circulate between avian or mammalian
amplifying hosts and mosquito or tick vectors. Based on
differences in reactivity in immunological tests, the flaviviruses
have been classified into four distinct antigenic complexes.
The flavivirus genome is a single-stranded capped RNA of
positive polarity lacking a 3′ terminal poly(A) sequence. It
encodes a single polypeptide that is co- and post-translationally
processed into viral structural proteins, C, prM/M, and E, that
form the viral particle, and the nonstructural proteins, NS1,
NS2A, NS2B, NS3, NS4A, NS4B and NS5, required for
replication of viral genome (Lindenbach and Rice, 2001).⁎ Corresponding author. Fax: +1 409 772 5065.
E-mail address: ivfrolov@utmb.edu (I. Frolov).
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0042-6822/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2006.04.003Virions contain a single copy of viral genomic RNA
packaged into nucleocapsid formed by the C protein,
surrounded by lipid envelope holding dimers of E and the M
protein. In contrast to many other enveloped viruses, interaction
between nucleocapsid and envelope spikes is not very specific
and M/E-containing envelope can efficiently form around
nucleocapsid derived from a heterologous flavivirus, demon-
strating limited level of homology in C sequence (Chambers et
al., 1999; Lorenz et al., 2002; Monath et al., 2002).
Alternatively, expression of prM and E in the absence of C
can lead to formation of subviral particles (SVPs), containing no
RNA or C protein (Mason et al., 1991). PrM/M-E cassettes
producing SVPs have been the basis of several effective subunit
(Konishi and Fujii, 2002; Konishi et al., 2001, 1992b; Qiao et
al., 2004), DNA (Aberle et al., 1999; Colombage et al., 1998;
Davis et al., 2001; Kochel et al., 1997, 2000; Konishi et al.,
2000a, 2000b; Phillpotts et al., 1996; Schmaljohn et al., 1997),
and live-vectored (Colombage et al., 1998; Fonseca et al., 1994;
Kanesa et al., 2000; Konishi et al., 1992a; Mason et al., 1991;
Minke et al., 2004; Pincus et al., 1992; Pugachev et al., 1995)
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is their high safety, but they have been proved difficult to
produce in large quantities. DNA vaccines have been poorly
immunogenic, and viral vectored vaccines have suffered from
lack of potency in the presence of vector immunity.
In spite of a great concern about flavivirus-associated
diseases and continuing spread of flaviviruses into new areas,
antiviral therapeutics have not been developed yet for these
infections, and a very limited number of approved vaccines
have been produced to date. Inactivated viral vaccines (INVs)
have been licensed to prevent tick-borne encephalitis (TBEV)
and Japanese encephalitis (JEV). However, like other INVs,
these vaccines have limited potency and require multiple
vaccinations. Despite these drawbacks, the JEV and TBEV
INVs have the advantage of good safety records.
The only live-attenuated vaccine (LAV) for a flavivirus
that is licensed for use in the United States is the widely
utilized yellow fever virus (YFV) 17D strain that was
developed by serial passaging of the wt Asibi strain of
YFV in chicken embryo tissues (Monath, 1991). Although
this LAV is considered very safe and effective, there have
been cases of YF in vaccinees, including a recent case in a
US military recruit (Gerasimon and Lowry, 2005). Further-
more, this vaccine is not recommended to use in infants,
pregnant women, or the immunocompromised individuals,
due to possible adverse events, including vaccine-associated
encephalitis.
The development of the reverse genetics systems for
flaviviruses has opened an opportunity for the designing of
new types of LAV, based on rational attenuation of these
viruses. This new class of vaccines includes YFV 17D-based
chimeras, in which the YFV prM-E-encoding genome fragment
has been replaced with the prM-E-cassette derived from
heterologous flaviviruses (Chambers et al., 1999). Similar
chimeric virus-based approach was applied for dengue- and
TBEV-based backbones (Huang et al., 2003; Pletnev et al.,
2002). In most cases, chimeric flaviviruses demonstrate a highly
attenuated phenotype and are capable of eliciting efficient
protective immune response and protect against following
infection with viruses, whose structural proteins are expressed
by the chimeras (Monath et al., 2002). Effective vaccination
with these chimeric vaccine candidates does not appear to be
prevented by pre-existing “vector” immunity (Monath et al.,
2002), which has interfered with potency of recombinant viral
vaccines based on other viral vectors (see above). Although
chimeric flaviviruses might provide a reasonably universal
approach to producing new vaccines, there are concerns that the
chimeras themselves will be pathogenic (Chambers et al., 1999)
at least in the immunocompromised individuals, or that
pathogenic chimeras may arise, since mutations have been
detected during the process of propagation of these viruses
(Pugachev et al., 2004).
Another promising direction in vaccine development is
based on creating irreparable deletions in flavivirus genome
that make productive virus replication in the vaccinated host
either less efficient or impossible. In the latter case, viral
genomes encoding the entire replicative machinery, butlacking, for instance, the C-coding region, can be delivered
for in vivo immunization as in vitro-synthesized RNA,
capable of self-replication (Aberle et al., 2005; Kofler et al.,
2004). Alternatively, they could also be delivered in cDNA
form under control of the RNA polymerase II promoters, a
method that has been used to produce infectious flaviviruses
by other researchers (Hall et al., 2003; Mishin et al., 2001).
Direct immunization with in vitro-synthesized defective RNA
genomes, which specifies the production of SVPs in the
absence of a complete viral replication cycle, has been
demonstrated to be safe and effective in producing protective
immunity (Aberle et al., 2005; Kofler et al., 2004). However,
there may be significant obstacles to producing an RNA-based
vaccine candidate, due to synthesis, stability, and delivery
issues.
In the present work, we describe the development of the C-
deleted flavivirus genomes into a new type of vaccine with the
safety of INV and the efficacy, stability, and scalability of LAV.
These products consist of particles containing genomes lacking
a large portion of C-encoding region. They can be propagated to
high titers in cell lines expressing either C, or a C-prM-E
cassette. However, they cannot develop spreading infection in
normal cells in vitro or in vivo, in the absence of trans-
complementation by C. Based on their noninfectious nature in
normal cell lines, we have named these particles pseudoinfec-
tious viruses (PIVs). PIVs derived from YFV and West Nile
virus (WNV) produce SVPs containing the E protein. YF and
WN PIVs did not cause disease or death in baby or adult mice.
Adult mice inoculated with WN PIVs produced high levels of
neutralizing (NEUT) antibody, indicating a single round of
replication in vivo and release of SVPs, and animals vaccinated
with the WN PIVs were protected from lethal encephalitis after
challenge with WNV.
Results
Both YFV C- and YFV C-prM-E-expressing cassettes can
complement replication of YF PIV
The general strategy for complementation of a C deletion
defect in the flavivirus genome is presented Fig. 1. It is based on
development of genomes lacking part of the C gene, and
propagation of these pseudoinfectious viral genomes (PIV
genomes) in cells expressing C (or all of the viral structural
proteins), but not in normal cells. Replication in the latter cells,
producing no viral structural proteins required for trans-
complementation of the defect in PIV genome, leads to release
of SVPs containing the critical protective immunogen E, but
lacking the nucleocapsid containing C and the viral genetic
material.
A recombinant YFV genome (YF PIV genome) was
engineered to contain GFP in place of a.a. 26–93 of C, cloned
in-frame with the rest of the polypeptide (Fig. 2A). The
expression of GFP provided us a convenient way of determining
the titers of genome-containing PIVs in our experiments. The
deletion in the C-coding sequence from this PIV genome was
expected to destroy the ability of C to form a functional
Fig. 2. YFV C and YFV C, prM and E-expressing cell lines can complement
replication of YF PIV. (A) Schematic representation of YFV and GFP-
expressing YF PIV genome (see Materials and methods for details). (B)
Schematic representation of VEEV replicons expressing Pac gene and YFV C
with the signal peptide of prM (anchored C; VEErep/C1/Pac), or anchored C
with 20 a.a. of prM (VEErep/C2/Pac), or all of the YFV structural proteins
(VEErep/C-prM-E/Pac). (C) The release of YF PIV by the cell lines transfected
with in vitro-synthesized PIV genome. Media were replaced at the indicated
time points, and titers of PIVs were determined as described in Materials and
methods. Arrows indicate time points when cells were subpassaged at a 1:5
ratio.
Fig. 1. Schematic representation of flavivirus PIV replication in the cells
producing C or all of the viral structural proteins for trans-complementation of
the defect. Replication of PIVs in normal cells in vivo or in vitro leads to release
SVPs having no nucleocapsid.
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functional forms of prM and E. Thus, cells expressing this
genome, which produced GFP fluorescence (data not shown),
could not release infectious virus. However, we expected that
infectious progeny could be produced from “packaging” cells
expressing high levels of C.
For rapid development of the cell lines for efficient PIV
production, we applied Venezuelan equine encephalitis virus
(VEEV) genome-based expression system (replicons) (Petra-
kova et al., 2005). The expression cassettes were designed as
double subgenomic constructs (Fig. 2B), in which one of the
subgenomic promoters was driving the expression of Pac,
providing an efficient means to eliminate cells in the transfected
cultures that do not contain the Pac-expressing VEEV replicon.
The second subgenomic promoter was driving the transcription
of subgenomic RNA encoding YFV structural proteins. To
identify the most efficient packaging cassettes, we engineered
VEEV replicons encoding either (i) YFV C with the signal
peptide of prM, also known as anchored C (Lindenbach and
Rice, 2001) (VEErep/C1/Pac), or (ii) C with the signal peptide
and 20 a.a. of prM (VEErep/C2/Pac), or (iii) all of the YFV
structural proteins (VEErep/C-prM-E/Pac).
The in vitro-synthesized VEEV replicon RNAs were
transfected into BHK-21 cells and the PurR stable cell lines
were selected over the next 4–5 days in the Pur-containing
medium. During the first 2–3 days post-transfection,
replication of VEEV-derived RNAs caused growth-arrest,then, as we described in our previous work (Petrakova et al.,
2005), replication became less efficient and cells resumed
their growth. The resulting PurR cultures were transfected
with the in vitro-synthesized YF PIV RNAs, and at different
times post-transfection, titers of the released infectious
particles, containing GFP-expressing genomes, were deter-
mined as described in Materials and methods (Fig. 2C).
Surprisingly, the presence of two different replicating RNAs
(YFV- and VEEV-specific) in BHK-21 cells did not result in
cytopathic effect (CPE) and maintained both resistance to Pur
and expression of high level of GFP, indicating replication of
both the VEEV replicon and YF PIV RNAs. As shown in
Fig. 2C, cultures expressing both of these marker genes were
capable of growing and required subpassaging (at ∼1:5 ratio
every 4 days) to prevent the cultures from reaching
Fig. 3. Growth curves of YF PIV on the packaging cell lines. BHK-21 cells
containing VEErep/C2/Pac and VEErep/C-prM-E/Pac replicons were infected
with YF PIVat indicated MOIs. At the indicated times, media were replaced and
titers of released PIV were determined as described in Materials and methods.
One of several similar experiments is displayed here. Arrows indicate time
points when cells were subpassaged at 1:5 ratio.
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that all three VEEV replicons were capable of supplying
YFV C at levels sufficient for formation of infectious PIVs;
no infectious particles were released from the naive BHK-21
cells transfected with the YF PIV RNA in the absence of
VEEV replicons (data not shown). However, cells expressing
these packaging cassettes differed in their ability to produce
PIV. Constructs expressing YFV C followed by the prM
signal peptide (anchored C; VEErep/C1/Pac) demonstrated
the lowest level of YF PIV RNA packaging, compared to
cassettes expressing longer protein sequences. Thus, we
elected to eliminate VEErep/C1/Pac from all further experi-
ments and concentrate on the other two cassettes. Both
VEErep/C2/Pac and VEErep/C-prM-E/Pac replicons pack-
aged YF PIV to the similar titers approaching above 107 inf.
u/ml. Moreover, the release of PIV particles continued until
the experiments were terminated. The same cells were
probably also releasing prM/E-containing SVPs lacking the
nucleocapsid and RNA, but this possibility was not further
investigated.
YF PIVs with defective genomes can be produced at a large
scale
To efficiently produce PIVs, we made use of a technology
that permits the production of alphavirus replicon-expressing
cell cultures using previously packaged VEEV replicons. To
this end, we packaged VEEV replicons into VEEV infectious
virions using previously described two-helper system (Volk-
ova et al., 2006), into preparations that contained titers
approaching 109 inf.u/ml. BHK-21 cells infected with these
particles and selected in the presence of Pur could be used to
obtain YFV structural protein-encoding cell cultures within 3–
5 days. Following establishment, these VEErep/C2/Pac- and
VEErep/C-prM-E/Pac-containing cell cultures were infected
with previously generated samples of YF PIVs at high (10 inf.
u/cell) and low (0.1 inf.u/cell) MOIs. In all cases, the
defective YFVs replicated productively (see Fig. 3) and
infected all of the cells in the monolayers, producing high
titers of PIVs.
Thus, rapid establishment of packaging cell lines by
infecting cells with packaged VEEV replicons, followed by
infection with PIVs, appears to be a simple and efficient system
for large-scale production of PIVs with the deleted C sequence
in the genome.
Production of YF PIVs using VEE replicons expressing codon-
optimized form of YFV C gene
Another possible problem in using the packaging systems to
support replication of defective viruses is recombination
between the defective viral genomes and the RNAs encoding
the trans-complementing gene(s). Such recombination might
lead to generation of the infectious viruses. In our experiments,
we were never able to detect infectious YFV using a plaque
assay, but the possibility that live virus can be formed in these
cells is important to rule out.In addition, the proteins encoded by many arthropod-borne
viruses are expected to have evolved to utilize the translational
machinery in two very different hosts. Thus, their codon usage
is not expected to be optimal for expression in either host.
Therefore, we modified the C-coding sequence in the
expression cassettes to achieve two goals: (i) to enhance the
yield of C production and (ii) to reduce possibility of
homologous recombination between YF PIV genome and C-
coding subgenomic RNA of VEE replicons. YFV C was
synthesized using the codon frequency found in the most
efficiently translated mammalian genes (Fig. 4A) (see Materials
and methods for details). These silent mutations also disrupted
the cyclization sequence required for flavivirus genome
replication, thus, reducing the possibility of generating
replication competent YFV in an event of recombination
between YF PIV genome and YFV C-coding RNA of VEEV
replicon.
Fig. 4. The use of cells expressing codon-optimized C gene for production of YF PIV. (A) Nucleotide sequence of synthetic gene. The introduced mutations are
indicated by lowercase letters. (B) Growth curves of YF PIVon the packaging cell lines. BHK-21 cells containing VEErep/C2/Pac, VEErep/C-prM-E/Pac, VEErep/
C2opt/Pac, and VEErep/Copt-prM-E/Pac replicons were transfected with in vitro-synthesized YF PIV RNA as described in Materials and methods. At the indicated
times, media were replaced and titers of released PIV were determined as described in Materials and methods. (C) Plaques developed in VEErep/C2opt/Pac-containing
cell line by YFV and YF PIV after 4 days of incubation at 37 °C.
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Copt/Pac and VEErep/Copt-prM-E/Pac, having the same
strategy as VEErep/C2/Pac and VEErep/C-prM-E/Pac, and
trans-complementing PurR cell lines were established either by
RNA transfection or by infecting the cells with packaged RNAs.
Transfection of these cells with the in vitro-synthesized PIV
genome RNA produced PIV with efficiencies that were similar
to those detected with the cells expressing VEEV replicons
expressing the nonoptimized YFV C gene (Fig. 4B). However,
the cells expressing the codon-optimized C proved to be a
useful reagent in that they were capable of developing CPE
and forming clearly visible plaques when infected with YF
PIV and overlaid with agarose containing media with low
concentration of FBS (Fig. 4C). Thus, although codon
optimization of YFV C gene did not alter PIV production
from these cells, the cells expressing the codon-optimized
YFV C represent a very useful system for evaluation of YF
PIVs, particularly those expressing no fluorescent markers. In
additional tests, we found a very good correlation between the
titers of the same samples determined in plaque-forming assays
and GFP-foci assays (data not shown). Plaques formed by YF
PIV were smaller than those of YFV indicating that, most
likely, structural proteins produced in cis function more
efficiently in viral particle formation. The reason for attaining
the ability to form plaques is not completely understood yet.
However, we can speculate that YFV C has some level of
cytotoxicity because the cell lines containing VEEV replicons
expressing the codon-optimized version of this proteindemonstrated slower growth rates (data not shown) than
corresponding counterparts with replicons encoding natural C
gene. Thus, YF PIV genome replication might lead to
additional changes in the intracellular environment that were
sufficient for causing CPE.
PIVs can be generated for other flaviviruses
To prove that PIVs can be easily generated for other
flaviviruses, we applied the strategy described above to
WNV. To this end, we created a WN PIV genome with a 35-
a.a.-long C protein (see Materials and methods; Fig. 5A). To
package this WN PIV genome, we used a packaging cell line
generated by transfection of BHK cells with a noncytopathic
VEEV replicon expressing WNV C/prM/E and Pac {BHK
(VEErep/C*-E*-Pac); Fayzulin et al., in press}. To minimize
the chance that recombination between WN PIV genomes
replicating in this cell line and the VEErep RNA-encoded C
protein could lead to generation of the infectious WNV, the
WNV C-coding gene in the VEEV replicon was modified to
contain clustered silent mutations in the WNV cyclization
domain (Fayzulin et al., in press).
Media harvested from BHK(VEErep/C*-E*-Pac) cells
transfected with our synthetic WN PIV genome were capable
of producing antigen-positive foci in the packaging cells (Fig.
5B) indicating that infectious WN PIV had been produced.
However, only single antigen-positive cells were detected
upon infection of Vero cell monolayers with the same samples
Fig. 5. WN PIV develops spreading infection in packaging cells. (A) Schematic representation of WN PIV genome and VEEV replicon expressing WNV structural
proteins (see Materials and methods for details). (B) WN PIV produced foci of WNV antigen-positive cells (revealed with an antibody to NS1; see Materials and
methods for details) upon infection of BHK(VEErep/C*-E*-Pac) cells after 70 h of incubation. (C) The sameWN PIV preparations produced only single infected cells
upon infection of Vero cell monolayers (revealed at 70 h post-infection).
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produced on the packaging cells, and as expected, WN PIV
could be repeatedly passaged on this cell line.
Thus, high titer stocks of WN PIV could be readily
obtained using the same complementation system described
above for YFV. Interestingly, in the case of the WNV
packaging cell line and WN PIV, we noted that virus yields
plateaued late in infection, simultaneously with the appearance
of CPE (data not shown), whereas the cells co-replicating YF
PIV genome and VEEV replicons continued to produce PIV
for many days (Fig. 2).
Cells infected with YF or WN PIVs produce SVPs
To demonstrate that cells infected with PIVs produced
SVPs, we either transfected BHK-21 cells with the in vitro-
synthesized YF PIV RNA or infected these cells with YF PIVs
produced in C-expressing cells. The particles released from the
BHK-21 cells were purified by ultracentrifugation as described
in the Materials and methods, and analyzed by Western
blotting using a mouse monoclonal antibody (MAB) specific
for E (D1-4G2; Gentry et al., 1982). Both RNA-transfected
and PIV-infected cells produced E protein that could be
pelleted from the media (Fig. 6A), indicating that it was
present in a particulate form. Since these cells did not exhibit
any CPE, and the samples were clarified at low-speed
centrifugation prior to ultracentrifugation, it is unlikely that
the E protein detected in the pelleted fraction represented
cellular debris. Similarly, Western blot analyses demonstrated
that Vero cells infected with the WN PIV produced (before
development of any signs of CPE) extracellular forms of E that
were indistinguishable in size from those produced by WNV-
infected Vero cells (Fig. 6B). To further evaluate the physical
nature of the E protein released by PIV-infected cells, mediacollected from cells containing replicating YFV PIV genomes
only were subjected to sucrose density gradient analyses. In
agreement with previously published data (Schalich et al.,
1996; Kofler et al., 2004), SVPs were found in the fraction
having 32% sucrose (Fig. 6C). In the same experiment, YFV
virions demonstrated higher density and were detected in the
fraction with 42% sucrose (data not shown). E protein-
containing particles that migrate at the expected size of WNV
SVPs have also been detected in cultures infected with WNV
PIVs (data not shown).
The presence of E in the media of PIV-infected cells is
consistent with the production of SVPs by cells expressing only
prM/E (see Introduction) or TBEV RNA vaccines lacking a
functional C gene (see Introduction).
PIV safety, potency, and efficacy in animals
Safety of WN and YF PIVs was established by i.c.
inoculation of litters of 3 to 4-day-old mice. These studies
showed that mice inoculated with WT YFV or WNV were
quickly killed, and these viruses displayed a 50% lethal dose
(LD50) of approximately 1 PFU in these animals (Table 1)).
However, WN and YF PIVs inoculated into suckling mice at a
dose of 2×106 inf.u failed to kill any of them (Table 1). Safety
was further documented by i.p. inoculation of adult mice with
wild type (wt) viruses and WN PIVs. These studies showed
that the WN PIVs were completely safe in adult mice (Table
2). Furthermore, wt WNV killed a significant portion of adult
mice, with an LD50 of less than 1 PFU, and doses of up to
3×106 inf.u of WN PIV failed to cause any death (Table 2).
Most interestingly, however, is the finding that the WN PIVs
were very potent immunogens (NEUT titers were detected
with inoculation of as few as 30,000 inf.u), and 100% of the
animals vaccinated with 3×104, 3×105, or 3×106 inf.u were
Fig. 6. Detection of E protein released from cells infected with YF and WN
PIVs. (A) BHK-21 cells were infected with YF PIV at an MOI of 5 inf.u/cell.
The released SVPs were harvested and purified by ultracentrifugation as
described in Materials and methods. Samples were resolved by SDS PAGE,
transferred to filters, and E protein was detected by D1-4G2 MAB. Media
harvested from uninfected cells, lane 1; media harvested from the cells infected
with YF PIV at 48 h post-infection, lane 2; media harvested from the cells
infected with YF PIVs at 72 h post-infection, lane 3; YFV (2×107 PFU), lane 4.
(B) Vero cells were infected with WN PIV for 24 h, and then portions of the
clarified culture fluid (collected before any cell lysis was detected) were resolved
by SDS PAGE, transferred to filters, and reacted with an E-specific MAB (7H2;
Bioreliance). Reaction of the same samples with polyclonal sera failed to reveal
any cell-associated nonstructural proteins in this preparation (data not shown)
confirming that the E protein was actively secreted. Sample of WNV, lane 1;
media harvested from uninfected cells, lane 2; media harvested from the cells
infected with WN PIVat 48 h post-infection, lane 3. (C) Western blot showing E
protein content of fractions prepared from a sucrose density gradient obtained
from SVPs harvested from normal (nonpackaging) BHK cells electroporated
with YFV PIV RNA (see Materials and methods). The peak of E protein
reactivity (at 32% sucrose) corresponded to the density of SVPs, and in
agreement with this fact, migrated more slowly than YFV run in a side-by-side
analyses (42%; see text).
Table 1
Safety of PIVs in suckling mice
Inoculuma Dose (inf.u) b % Survival c Average
survival time d
WN PIV 2,000,000 100 (9/9) NAe
WNV TX02 0.2 56 (5/9) 8.5 (+/−2.9)
WNV TX02 2 0 (0/9) 5.4 (+/−0.5)
WNV TX02 20 0 (0/8) 6 (+/−0)
WNV TX02 200 0 (0/10) 4.9 (+/−0.3)
YF PIV 2,000,000 100 (10/10) NAe
YFV 17D 0.2 89 (8/9) 8 (+/−0)
YFV 17D 2 56 (5/9) 7 (+/−0)
YFV 17D 20 11 (1/9) 6.9 (+/−2.4)
YFV 17D 200 0 (0/12) 6 (+/−0)
a Inoculated preparation, diluted in culture media with 10% FBS.
b Delivered by i.c. route in a volume of 20 μl/animal.
c Survival at 14 days post inoculation (live/dead).
d Average survival time from animals that died from infection (standard
deviation).
e Not applicable.
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strain of WNV (Table 2).
Discussion
Safe and effective vaccines have only been produced for a
handful of diseases caused by flaviviruses. The classical INVand
LAV methods that have been used to produce vaccines to JEV,
TBEV, and YFV have not yet yielded licensed products to
prevent diseases caused by other flaviviruses, notably dengue
and WNE. There remain safety concerns about existing LAV
(residual virulence or reversion to virulence) and INV products
(reactogenicity due to antigen load and adventitious antigens).
Both types of products are subject to production concerns,
including the need to avoid reversion to virulence during
propagation of LAV, and due to the amounts of material needed
to produce strong immune responses to the INV products, and
the need for high-containment facilities to propagate the virulent
viruses used to produce INV products. Although there arepromising candidates for new types of flavivirus vaccines, the
road to their development will need to overcome these problems.
In the present study, we have demonstrated that pseudoin-
fectious viruses, which we have termed PIVs, are unable to
cause disease in animals, but can be produced in a manner that
allows high-yield production in cell culture. These products can
be delivered to animals where their defective replication process
prevents spread and disease development, but leads to the
production of SVPs, a flavivirus subunit immunogen that has
been shown to be effective in eliciting an efficacious immune
response against disease caused by several flaviviruses (see
Introduction).
Our studies have demonstrated that the PIV approach can be
applied to two distantly related mosquito-borne flaviviruses. The
applicability of RNA-based vaccines for a tick-borne flavivirus
(Kofler et al., 2004) suggests that the PIV-based technology will
be applicable to more flaviviruses. The work with TBEV RNA-
based vaccines also indicates that in addition to antibody
responses to the SVPs (similar to those we documented in our
studies) the introduction of replicationally active flavivirus
genomes into the cells of the vaccinated hosts produces T-cell
responses as well (Aberle et al., 2005; Kofler et al., 2004).
Although we have not measured T-cell responses in our studies,
it is likely that PIVs are also capable of inducing T-cell responses
that mimic those produced by viral infection.
Although our PIV vaccines rely on the same flavivirus
replication and SVP production strategy that is utilized by the
RNA-based vaccines prepared for TBEV (Aberle et al., 2005;
Kofler et al., 2004), PIV vaccines do not require gene-gun
delivery to animals, can be readily grown in cell cultures, and
should be subject to the same types of stabilization and storage
(freeze drying) conditions currently being applied to the
commercially produced YFV 17D vaccine.
To develop the high-level growth conditions required for
efficient trans-complementation (and hence yield) of flavivirus
PIVs, we utilized cells expressing VEEV replicons. This system
appears to be suitable for production of PIVs, since (i) VEEV
replicons are efficient in synthesis of heterologous proteins and,
Table 2
Safety, potency and efficacy of PIV in adult mice
Inoculuma Dose (inf.u) b % Survival c Average survival time d NEUT titer e % Protection f
none (diluent) 0 100 (8/8) NAg <1:40h 14 (1/7)
WN PIV 30,000 100 (10/10) NAg 1:40 100 (8/8)
WN PIV 300,000 100 (10/10) NAg 1:160 100 (8/8)
WN PIV 3,000,000 100 (10/10) NAg 1:160 100 (8/8)
WNV TX02 1 40 (4/10) 8.5 (+/−1.4)
WNV TX02 10 30 (3/10) 8 (+/−1.2)
WNV TX02 100 10 (1/10) 7.8 (+/−1.4)
a Inoculated preparation, diluted in culture media with 10% FBS.
b Delivered by i.p. route in a volume of 100 μl/animal.
c Survival at 14 days post inoculation (live/dead).
d Average survival time from animals that died from infection (standard deviation).
e NEUT titer of pooled sera collected from 2 animals at 21 days post inoculation (titer shown is the highest dilution giving 80% reduction of WNV foci formation).
f Protection from challenge with 100 LD50 of the NY99 strain of WNV demonstrated by survival at 14 days post-challenge; single survivor from the diluent-
inoculated group showed signs of disease (hunched back, ruffled fur, and malaise) from days 8–14. None of the PIV inoculated animals displayed any signs of disease
in the 14-day post challenge observation period.
g Not applicable.
h NEUT titers in sera from unimmunized mice tested side-by-side with sera from the WN PIV-inoculated mice.
439P.W. Mason et al. / Virology 351 (2006) 432–443in our study, synthesized C to the level required for flavivirus
genome incapsidation. (ii) VEEV replicons do not detectably
interfere with flavivirus replication (Petrakova et al., 2005 and
data not shown). Moreover, VEEV replicons and the YF PIV
genomes can replicate together in BHK-21 cells without causing
CPE. (iii) VEEV replicons can be packaged to high-titers into
VEE virions that can be used for rapid establishment of the
packaging cell lines producing flavivirus structural protein(s).
Studies to examine the effect of the context of C expression
on yield of PIV production indicated that packaging cells
expressing the anchored form of C with an additional 20 a.a. of
prM produced more particles than cells expressing anchored C
alone, suggesting the importance of the proper sequence of
processing events in virion formation. The basis for the
enhanced packaging efficiency by the construct containing the
first 20 a.a. of prM is unclear, but this phenomenon might be
explained by a requirement for a specific ordering of cleavage at
the two nearby cleavage sites (NS2B/NS3- and signal
peptidase-specific) (Yamshchikov and Compans, 1994), and/
or differences in distribution/stability of the C protein produced
in these two different contexts. In addition, we noted that co-
expression of C together with prM and E (VEErep/C-prM-E/
Pac) caused only minor increase in PIV yield compared to
VEErep/C2/Pac, which expressed anchored C with the fragment
of prM.
Experiments which tested the ability of codon-optimization
in the VEEV replicon-encoded C genes were undertaken to
determine if this alteration of the C gene sequence would
enhance yield of PIV. These experiments did not reveal a strong
difference in YFV PIVrelease from the cells expressing a codon-
optimized C gene, suggesting that even with the nonoptimized
gene, VEEV replicons appear to produce C at a saturating level.
These results are consistent with other studies demonstrating the
cell lines that express VEEV replicons encoding the WNV C-E
cassette produce level of E greater than those detected in WNV-
infected cells (Fayzulin et al., in press). Despite the inability of
the trans-expressed optimized C gene to increase yield of YF
PIV, the cells harboring the VEEV replicon expressing Coptdeveloped CPE and produced plaques when infected with YF
PIV. This made a PIV infection in the Copt cells even more
similar to infection developed by replication-competent virus.
An additional advantage of the use of VEEV replicons encoding
a YFV Copt gene in PIV production was at the level of safety,
since the changes in the codons would reduce the chance of
homologous recombination with the PIV genome. Furthermore,
the Copt gene was also altered in its cyclization sequence [as was
done for theWNVC coding region in our BHK(VEErep/C*-E*-
Pac) cells], to reduce the chance that recombination could
produce a replicationally active C-encoding flavivirus. To date,
none of our studies with either the WN or YF PIV systems has
produced replication-competent flaviviruses that could be
detected in either cell culture or in highly susceptible animals.
Animal experiments demonstrated that both YF and WN
PIVs are safe and could not cause any disease even after i.c.
inoculation of 3- to 4-day-old mice with the highest doses of the
PIVs that we could prepare. Nevertheless, WN PIVs were
capable of inducing high level of neutralizing antibodies and
protected mice against infection with a highly virulent strain of
WNV.
In conclusion, we demonstrated that C-deficient, pseudoin-
fectious flaviviruses (i) produced a spreading infection in the cell
lines expressing C or all of the viral structural genes. (ii) PIVs
were incapable of producing spreading infection in normal cells.
(iii) PIVs produced E protein-containing SVPs when they
infected normal cells. (iv) PIVs displayed a very high level of
safety in the animals. (v) PIVs protected mice against subsequent
flavivirus infection. Taken together, these studies demonstrated
that flavivirus PIVs are a safe, potent, and efficacious platform for
development of vaccines to protect against flavivirus infections.
Materials and methods
Cell cultures
The BHK-21 cells were kindly provided by Paul Olivo
(Washington University, St. Louis, MO). They were maintained
440 P.W. Mason et al. / Virology 351 (2006) 432–443at 37 °C in alpha minimum essential medium (αMEM)
supplemented with 10% fetal bovine serum (FBS) and vitamins.
Vero cells were maintained in MEM containing 6% FBS.
Plasmid constructs
Standard recombinant DNA techniques were used for all
plasmid constructions. Maps and sequences are available from
the authors upon request. The parental low-copy number
plasmid pACNR/FLYF-17Dx containing infectious cDNA of
YFV 17D strain genome was described elsewhere (Breden-
beek et al., 2003) and kindly provided by Dr. Charles M. Rice
(Rockefeller University, New York). pYFPIV contained a
defective YFV genome (YF PIV), in which a fragment
encoding a.a. 26–93 of YF capsid gene was replaced by
codon-optimized GFP gene derived from pEGFP-N1 (Clon-
tech). The WN PIV genome (pWNPIV) was derived from a
Texas 2002 infectious cDNA (Rossi et al., 2005), by fusion of
codon 30 of C to codon 101 of C (see Fig. 5A). The plasmids
pVEErep/C1/Pac, pVEErep/C2/Pac, and pVEErep/C-prM-E/
Pac (Fig. 2A) encoded double subgenomic VEEV replicons,
in which the first subgenomic promoter was driving
transcription of the RNAs containing 5′UTR of VEEV 26S
RNA followed by sequences, corresponding to nt 119–481,
119–541, and 119–2452 of YFV genome, respectively. The
second subgenomic promoter was driving the expression of
puromycin acetyltransferase (Pac) gene, whose product was
making cells resistant to translational arrest caused by
puromycin (Pur). The codon-optimized sequence encoding
YFV 17D capsid and first 20 a.a. of prM was designed using
the codon frequency data described elsewhere (Haas et al.,
1996). This gene was synthesized by PCR from the
overlapping synthetic oligonucleotides. The amplified frag-
ment was sequenced before cloning into expression cassettes
VEErep/C2opt/Pac and VEErep/Copt-prM-E/Pac. The latter
replicons had essentially the same design as pVEErep/C2/Pac
and pVEErep/C-prM-E/Pac, but contained codon-optimized
sequence presented in Fig. 4A. pVEErep/C*-E*-Pac was
created from a VEEV noncytopathic replicon (Petrakova et
al., 2005), in which the C-prM-E-coding cassette of WNV
(derived from a Sindbis virus replicon; Scholle et al., 2004)
was fused to the Pac gene through a linker consisting of the
first 9 codons of NS1 and the last 25 codons of NS2B,
followed by 2 codons of NS3 fused directly to FMDV 2A
(see Fig. 5A) (Fayzulin et al., in press).
RNA transcriptions
Plasmids were purified by centrifugation in CsCl gradients.
Before the transcription reaction, plasmids were linearized by
XhoI (for pYFPIV), MluI (for VEE replicon and VEE helper
encoding plasmids), or SwaI (for pWNPIV). RNAs were
synthesized by SP6 or T7 RNA polymerase in the presence of
cap analog. The yield and integrity of transcripts were analyzed
by gel electrophoresis under nondenaturing conditions. Ali-
quots of transcription reactions were used for electroporation
without additional purification.RNA transfections and PIV replication analysis
Electroporation of BHK-21 cells was performed under
previously described conditions (Liljestrom et al., 1991). For
establishing packaging cell cultures, Pur was added to the media
to a concentration of 10 μg/ml at 24 h post-electroporation of
the VEEV replicons. Transfection of in vitro-synthesized YF
PIV genome was performed 5 days later, when replicon-
containing cells resumed efficient growth. Samples were
harvested at the time points indicated in the figures by replacing
the media with the same media, containing no Pur. In many
experiments, PIV-secreting cells were split upon reaching the
confluency.
VEEV replicons were packaged into VEEV infectious
virions by co-electroporation of the in vitro-synthesized
replicon and 2 helper RNAs (Volkova et al., 2006) into
BHK-21 cells. Replicon-containing viral particles were
harvested 24 h post-transfection and used for infecting of
naïve BHK-21 cells, followed by Pur selection. In the case of
WN PIV, the in vitro-synthesized PIV RNA was transfected
into BHK cells containing VEErep/C*-E*-Pac replicon
expressing WN C, prM, and E and Pac [BHK(VEErep/C*-
E*-PAC) cells]. This replicon is described in details elsewhere
(Fayzulin et al., in press), and the scheme of its genome is
presented in Fig. 5A. Harvested PIVs were passaged on these
cells using standard methods (Rossi et al., 2005).
Measuring the titers of YF PIV
For measuring the titers of released YF PIV, BHK-21
cells were seeded into six-well Costar dishes at a
concentration of 5×105 cells/well. Four hours later, cells
were infected with different dilutions of packaged replicons,
and, after 1 h incubation at 37 °C in an 5% CO2 incubator,
they were overlaid with 2 ml of αMEM supplemented with
10% FBS. The numbers of infected cells were estimated by
counting GFP-positive cells under an inverted UV micro-
scope. The fraction of infected cells was determined via
counting of fluorescence-producing cells in a defined area of
microscopic field. Counts for 5 different fields were
averaged and recalculated for the titer corresponding to
each serial dilution.
In the later experiments, titers were also measured by plaque
assay on the monolayers of BHK-21 cells, carrying VEErep/
Copt-prM-E/Pac replicon, using previously described condi-
tions (Lemm et al., 1990), except cells were incubated under
agarose for plaque development for 5 days, then fixed by 2.5%
formaldehyde and stained with crystal violet.
Passaging of YF PIVs
Packaging cell lines were established either by transfec-
tion of the in vitro-synthesized VEEV replicon RNAs or by
infecting cells with the same replicons packaged into
VEEV structural proteins at a multiplicity of infection
(MOI) of 10 inf.u/cell. After Pur selection, they were
infected with YF PIV at different MOIs. Samples were
441P.W. Mason et al. / Virology 351 (2006) 432–443harvested at the time points indicated in the figures by
replacing the media.
Analysis of YF SVP production
BHK-21 cells were seeded at a concentration of 2×106 per
100-mm dish. After 4 h incubation at 37 °C, cells were infected
with YF PIV at an MOI of 10 inf.u/cell, and then incubated for
24 h in 10 ml of αMEM supplemented with 10% FBS. Then the
medium was replaced by 10 ml of serum-free medium VP-SF
(Invitrogen) that was replaced every 24 h to analyze SVP release.
The collected VP-SF samples were clarified by low-speed
centrifugation (5000 rpm, 10 min, 4 °C), and then concentrated
by ultracentrifugation through 2 ml of 10% sucrose, prepared on
PBS, in SW-41 rotor at 39,000 rpm, 4 °C for 6 h. Pellet material
was dissolved in the loading buffer for SDS-polyacrylamide gel
electrophoresis, lacking β-mercaptoethanol (to preserve binding
to D1-4G2 MAB) and further analyzed by Western blotting.
After protein transfer, the nitrocellulose membranes were
processed by D1-4G2 MAB, and horseradish peroxidase
(HRP)-conjugated secondary donkey anti-mouse antibodies
purchased from Santa Cruz Biotechology. HRP was detected
using the Western Blotting Luminol Reagent according to the
manufacurer's recommendations (Santa Cruz Biotechnology).
To obtain positive control sample, YFV (2×108 PFU) was
subjected to ultracentrifugation through 10% sucrose cushion as
described above for SVPs. For sucrose density gradient analyses
of YFV SVPs, BHK-21 cells were electroporated with the in
vitro-synthesized YF PIV genome RNA. At 24 h post-
transfection, the complete αMEM was replaced by VP-SF
medium, which was harvested 24 h later. At this time, more than
95% of the cells were GFP-positive and did not exhibit any signs
of CPE. The harvested sample was clarified by low-speed
centrifugation (5000 rpm, 10 min, 4 °C), and then concentrated
by overnight centrifugation in SW-28 rotor at 25,000 rpm, 4 °C.
The resulting pellet was suspended in TN buffer (10 mM Tris–
HCl [pH 7.5], 100 mM NaCl, 0.1% BSA) and further analysis
was performed as previously described (Schalich et al., 1996).
Briefly, the 0.5 ml samples were loaded to the discontinuous
sucrose gradient (1.5 ml of 50%, 1.5 ml of 35%, and 1.5 ml 10%
sucrose prepared on PBS buffer). Centrifugation was performed
in SW-55 rotor at 45,000 rpm at 4 °C for 4 h. After fractionation,
samples were diluted 3-fold with PBS and SVPs were pelleted
by centrifugation in TLA-55 rotor at 45,000 rpm at 4 °C for 1 h in
Optima MAX Ultracentrifuge (Beckman). Pellets were dis-
solved in the loading buffer for SDS-polyacrylamide gel
electrophoresis, lacking β-mercaptoethanol (to preserve binding
to D1-4G2 MAB) and further analyzed by Western blotting.
After protein transfer, the nitrocellulose membranes were
processed by D1-4G2 MAB, and horseradish peroxidase
(HRP)-conjugated secondary donkey anti-mouse antibodies
purchased from Santa Cruz Biotechology. HRP was detected
using the Western Blotting Luminol Reagent according to the
manufacurer's recommendations (Santa Cruz Biotechnology).
Side-by-side gradient analyses were performed with YFV
(2×108 PFU), subjected to the same procedures as described
above for YFV-PIV-derived SVPs.Analyses of WN PIV
Titers of WN PIV were determined by infecting Vero cell
monolayers with serial dilutions of virus, and then fixing 24 h
later and immunohistochemically staining with a polyclonal
hyperimmune mouse ascite fluid specific for WNV, as
previously described (Rossi et al., 2005). Infected cells were
enumerated and used to determine the titer. To evaluate the
ability of WN PIV for foci formation on Vero cells or the BHK
(VEErep/C*-E*-PAC) cells, monolayers were infected with
dilutions of WN PIV, overlaid with a semisolid tragacanth
overlay, incubated at 37 °C, and then fixed and stained with a
MAB specific for WNV NS1 (generously provided by E.
Konishi, Kobe, Japan), as described above.
PIV safety studies
PIV safety was established by inoculation of different doses of
virus (YFV 17D orWNVTX02 recovered from parental infectious
cDNAs) or PIV into 3- to 4-day-old mice (outbred Swiss Webster,
Harlan) by the intracranial (i.c.) route (20 μl volume), or 4–5 week
old female mice (outbred Swiss Webster, Harlan) by the
intraperitoneal (i.p.) route (100 μl volume). Mice were monitored
for 14 days for signs of disease and death, and animals that were
moribund and appeared to be unable to survive until the next day
were humanely euthanized and scored as “dead” the following day,
in compliance with UTMB Animal Care and Use requirements.
WN PIV potency and efficacy studies
Selected animals inoculated with WN PIVas described above
were euthanized and bled at 21 days post-inoculation. Sera were
harvested from the animals, pooled, and tested for their ability to
reduce WNV focus formation on Vero cell monolayers using the
methods described above. The remaining animals were inocu-
lated with 1000 inf.u (determined by focus-forming assay on
Vero cells), corresponding to approximately 100 LD50 of the
NY99 strain of WNV (Xiao et al., 2001), and animals were then
observed for an additional 14 days as described above.
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